Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
During recent years combining GLP-1 and glucagon receptor agonism with the purpose of achieving superior weight loss and metabolic control compared to GLP-1 alone has received much attention. The superior efficacy has been shown by several in preclinical models but has been difficult to reproduce in humans. In this paper, we present the pre-clinical evaluation of NN1177, a long-acting GLP-1/glucagon receptor co-agonist previously tested in clinical trials. To further investigate the contribution from the respective receptors, two other co-agonists (NN1151, NN1359) with different GLP-1-to-glucagon receptor ratios were evaluated in parallel. In the process of characterizing NN1177, species differences and pitfalls in traditional pre-clinical evaluation methods were identified, highlighting the translational challenges in predicting the optimal receptor balance in humans. In diet-induced obese (DIO) mice, NN1177 induced a dose-dependent body weight loss, primarily due to loss of fat mass, and improvement in glucose tolerance. In DIO rats, NN1177 induced a comparable total body weight reduction, which was in contrast mainly caused by loss of lean mass, and glucose tolerance was impaired. Furthermore, despite long half-lives of the three co-agonists, glucose control during steady state was seen to depend on compound exposure at time of evaluation. When evaluated at higher compound exposure, glucose tolerance was similarly improved for all three co-agonists, independent of receptor balance. However, at lower compound exposure, glucose tolerance was gradually impaired with higher glucagon receptor preference. In addition, glucose tolerance was found to depend on study duration where the effect of glucagon on glucose control became more evident with time. To conclude, the pharmacodynamic effects at a given GLP-1-to-glucagon ratio differs between species, depends on compound exposure and study length, complicating the identification of an optimally balanced clinical candidate. The present findings could partly explain the low number of clinical successes for this dual agonism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, the influence of GcgR agonism to influence maximal weight lowering efficacy was readily apparent with the recently-reported clinical GLP-1/Gcg co-agonist 18 [50], as well as a sharp differentiation in performance between balanced triple agonist 16 and imbalanced triple agonist 19.”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“however, recent studies have highlighted challenges in achieving this balance [19,25].”
The cited source says what the claim attributes to it.
In the citing paper
“The glucagon/GLP-1 receptor co-agonist NNC9204-1177 (hereafter NN1177) with 2- to 4-fold higher affinity for GLP-1 than glucagon receptors was developed as a novel pharmacotherapeutic option for weight management [25].”
The cited source says what the claim attributes to it.
In the citing paper
“Preclinical evaluation of NN1177 revealed a complex picture of variability of compound exposure and study length when determining the optimal receptor balance [25],”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Clinical research on GLP-1/ glucagon receptor co-agonists also reveals clear decreases in amino acid levels (Parker et al, 2020;Simonsen et al, 2022).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Simonsen et al, 2022
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 1×
“Several long-acting GLP-1 receptor agonists have been clinically approved for the treatment of type 2 diabetes [9] and more recently also for the treatment of obesity (Saxenda1 and Wegovy1).”
BackgroundGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“GLP-1, produced and secreted by intestinal L-cells in response to nutrients, improves glucose homeostasis [7], while simultaneously lowering body weight by reducing energy intake [8].”
BackgroundDiscovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 1×
“A longer plasma half-life was secured by the attachment of a C18 fatty diacid, in line with the once-weekly GLP-1 receptor agonist semaglutide [21].”
BackgroundSelf-citationTHE ROLE OF RECEPTOR KINASES AND ARRESTINS IN G PROTEIN–COUPLED RECEPTOR REGULATION
Krupnick, J. G., & Benovic, J. L. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.289 · Cited by 1,103
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Self-citationCourcoulas, A. P. (2013) · JAMA · doi:10.1001/jama.2013.280928 · Cited by 799
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2390 · Cited by 435
Cited by
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 152
“Furthermore, the influence of GcgR agonism to influence maximal weight lowering efficacy was readily apparent with the recently-reported clinical GLP-1/ Gcg co-agonist 18 [50], as well as a sharp differentiation in performance between balanced triple agonist 16 and imbalanced triple agonist 19.”
MethodZimmermann, T., Thomas, L., Baader-Pagler, T., Haebel, P., Simon, E., Reindl, W., Bajrami, B., Rist, W., Uphues, I., Drucker, D. J., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101633 · Cited by 149
“Importantly, the GCGR agonistic activity of BI 456906 improved, rather than compromised, glycemic control in DIO mice, a profile that appears specific to BI 456906 as this was not observed for other long-acting GCGR/GLP-1R agonists [34].”
BackgroundMin, J. S., Jo, S. J., Lee, S., Kim, D. Y., Kim, D. H., Lee, C. B., & Bae, S. K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s506957 · Cited by 132
Targeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 127
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Nogueiras, R., Nauck, M. A., & Tschöp, M. H. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00812-z · Cited by 102
Metadata
- Authors
- Simonsen, L., Lau, J., Kruse, T., Guo, T., McGuire, J., Jeppesen, J. F., Niss, K., Sauerberg, P., Raun, K., & Dornonville de la Cour, C.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2022-03-04
- Volume
- 17
- Issue
- 3
- Pages
- e0264974
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC8896685
- OpenAlex
- W4214815915
- Cited by
- 36
- References
- 40
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 10 · 2023: 7 · 2022: 5
- FWCI
- 5.37
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- obesity, weight loss, glucose tolerance, diet-induced obesity, species differences, pharmacodynamics, lean mass loss, fat loss, translational research, study duration
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Blood Glucose, Glucagon, Mice, Obese, Obesity, Weight Loss, Receptors, Glucagon, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls. https://app.cochat.ai/papers/10.1371/journal.pone.0264974
- The paper
- Simonsen, L., Lau, J., Kruse, T., Guo, T., McGuire, J., Jeppesen, J. F., Niss, K., Sauerberg, P., Raun, K., & Dornonville de la Cour, C. (2022). Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls. PLOS ONE. https://doi.org/10.1371/journal.pone.0264974
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.